paliperidone palmitate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4498	199739-10-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: paliperidone palmitate RO92670 invega sustenna	A benzisoxazole derivative and active metabolite of RISPERIDONE that functions as a DOPAMINE D2 RECEPTOR ANTAGONIST and SEROTONIN 5-HT2 RECEPTOR ANTAGONIST. It is an ANTIPSYCHOTIC AGENT used in the treatment of SCHIZOPHRENIA. Molecular weight: 664.91 Formula: C39H57FN4O4 CLOGP: 9.34 LIPINSKI: 2 HAC: 8 HDO: 0 TPSA: 88.24 ALOGS: -4.98 ROTB: 20 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

paliperidone palmitate
RO92670
invega sustenna

A benzisoxazole derivative and active metabolite of RISPERIDONE that functions as a DOPAMINE D2 RECEPTOR ANTAGONIST and SEROTONIN 5-HT2 RECEPTOR ANTAGONIST. It is an ANTIPSYCHOTIC AGENT used in the treatment of SCHIZOPHRENIA.

Molecular weight: 664.91
Formula: C39H57FN4O4
CLOGP: 9.34
LIPINSKI: 2
HAC: 8
HDO: 0
TPSA: 88.24
ALOGS: -4.98
ROTB: 20

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
July 31, 2009	FDA	JANSSEN PHARMS
Sept. 20, 2013	PMDA	JANSSEN PHARMACEUTICAL K.K.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood prolactin increased	1895.99	30.45	372	14086	2937	56274672
Galactorrhoea	1770.27	30.45	361	14097	3534	56274075
Amenorrhoea	977.69	30.45	261	14197	8725	56268884
Injection site nodule	925.64	30.45	208	14250	3311	56274298
Schizophrenia	774.84	30.45	225	14233	10274	56267335
Product dose omission issue	585.06	30.45	455	14003	204298	56073311
Blood prolactin abnormal	549.59	30.45	125	14333	2100	56275509
Inappropriate schedule of product administration	521.33	30.45	302	14156	83085	56194524
Psychotic disorder	472.13	30.45	190	14268	23368	56254241
Disturbance in social behaviour	430.48	30.45	109	14349	2932	56274677
Hospitalisation	419.69	30.45	253	14205	74747	56202862
Anosognosia	383.89	30.45	94	14364	2195	56275414
Hyperprolactinaemia	367.95	30.45	100	14358	3561	56274048
Sexual dysfunction	366.15	30.45	98	14360	3290	56274319
Off label use	348.46	30.45	556	13902	555624	55721985
Hallucination, auditory	346.38	30.45	125	14333	11399	56266210
Dystonia	340.91	30.45	126	14332	12295	56265314
Metabolic disorder	311.41	30.45	96	14362	5365	56272244
Injection site mass	307.42	30.45	127	14331	16666	56260943
Extrapyramidal disorder	305.07	30.45	116	14342	12240	56265369
Personality change	297.12	30.45	94	14364	5723	56271886
Sedation	282.46	30.45	150	14308	34704	56242905
Akathisia	279.41	30.45	99	14359	8553	56269056
Incorrect dose administered	277.57	30.45	171	14287	52376	56225233
Weight increased	272.25	30.45	314	14144	229389	56048220
Breast discharge	258.49	30.45	57	14401	824	56276785
Dyskinesia	257.88	30.45	133	14325	28975	56248634
Treatment noncompliance	254.77	30.45	137	14321	32486	56245123
Syringe issue	214.06	30.45	60	14398	2396	56275213
Psychotic symptom	198.30	30.45	50	14408	1319	56276290
Suicide attempt	193.98	30.45	142	14316	57694	56219915
Tardive dyskinesia	186.02	30.45	72	14386	7959	56269650
Delusion	182.38	30.45	78	14380	11137	56266472
Paranoia	182.27	30.45	77	14381	10667	56266942
Refusal of treatment by patient	174.29	30.45	61	14397	5077	56272532
Injection site pain	172.90	30.45	180	14278	116938	56160671
Product use in unapproved indication	167.20	30.45	193	14265	140629	56136980
Device leakage	129.55	30.45	52	14406	6323	56271286
Schizoaffective disorder	127.47	30.45	42	14416	2907	56274702
Underdose	121.96	30.45	76	14382	23681	56253928
Blood glucose increased	120.77	30.45	121	14337	75030	56202579
Therapeutic response decreased	119.75	30.45	103	14355	52655	56224954
Diarrhoea	111.52	30.45	16	14442	638491	55639118
Aggression	109.44	30.45	69	14389	21937	56255672
Product administered at inappropriate site	107.32	30.45	36	14422	2634	56274975
Nausea	103.58	30.45	34	14424	764144	55513465
Pain	90.69	30.45	29	14429	663155	55614454
Arthralgia	82.04	30.45	15	14443	501654	55775955
Accidental exposure to product	81.37	30.45	60	14398	24587	56253022
Product quality issue	80.31	30.45	66	14392	31670	56245939
Drooling	79.74	30.45	31	14427	3463	56274146
Injection site abscess	78.78	30.45	23	14435	1063	56276546
Injection site reaction	75.14	30.45	80	14378	53167	56224442
Insurance issue	73.83	30.45	30	14428	3762	56273847
Injection site swelling	71.48	30.45	71	14387	43507	56234102
Abnormal behaviour	66.13	30.45	49	14409	20223	56257386
Condition aggravated	63.89	30.45	214	14244	344684	55932925
Fatigue	63.18	30.45	66	14392	788486	55489123
Hallucination	60.93	30.45	69	14389	49080	56228529
Parkinsonism	60.54	30.45	35	14423	9511	56268098
Breast enlargement	59.91	30.45	20	14438	1441	56276168
Abdominal discomfort	58.88	30.45	3	14455	277271	56000338
Injection site induration	58.42	30.45	33	14425	8582	56269027
Suicidal ideation	58.29	30.45	73	14385	57669	56219940
Neuroleptic malignant syndrome	57.07	30.45	36	14422	11442	56266167
Headache	56.81	30.45	37	14421	559007	55718602
Joint swelling	56.10	30.45	5	14453	289795	55987814
Dyspnoea	52.76	30.45	45	14413	592532	55685077
Imprisonment	51.88	30.45	12	14446	217	56277392
Cough	51.65	30.45	4	14454	259957	56017652
Product leakage	51.61	30.45	15	14443	682	56276927
Lactation disorder	51.36	30.45	13	14445	348	56277261
Drug ineffective	51.26	30.45	406	14052	918583	55359026
Drug intolerance	50.10	30.45	5	14453	264813	56012796
Needle issue	50.06	30.45	30	14428	8708	56268901
Drug hypersensitivity	50.03	30.45	6	14452	275199	56002410
Breast tenderness	48.83	30.45	19	14439	2126	56275483
Prolactin-producing pituitary tumour	48.54	30.45	10	14448	102	56277507
Tremor	48.06	30.45	100	14358	120989	56156620
Wrong technique in product usage process	45.60	30.45	65	14393	58103	56219506
Menstruation irregular	44.72	30.45	25	14433	6371	56271238
Vomiting	44.11	30.45	38	14420	498190	55779419
Abnormal weight gain	43.86	30.45	16	14442	1499	56276110
Abdominal pain	43.84	30.45	7	14451	258798	56018811
Product administration error	43.70	30.45	39	14419	20890	56256719
Anaemia	43.63	30.45	8	14450	267503	56010106
Adverse event	43.58	30.45	62	14396	55314	56222295
Product use issue	43.20	30.45	125	14333	185916	56091693
Nasopharyngitis	42.24	30.45	4	14454	220955	56056654
Psychiatric decompensation	41.99	30.45	15	14443	1323	56276286
Social avoidant behaviour	40.37	30.45	18	14440	2834	56274775
Mania	37.91	30.45	28	14430	11492	56266117
Catatonia	37.63	30.45	19	14439	3945	56273664
Pyrexia	36.96	30.45	32	14426	418741	55858868
Back pain	36.77	30.45	8	14450	237162	56040447
Pituitary tumour benign	36.67	30.45	15	14443	1913	56275696
Pruritus	36.32	30.45	18	14440	316605	55961004
Blunted affect	35.84	30.45	9	14449	233	56277376
Pneumonia	34.85	30.45	32	14426	407066	55870543
Peripheral swelling	34.26	30.45	9	14449	234717	56042892
Breast engorgement	32.28	30.45	7	14451	93	56277516
Adverse drug reaction	32.16	30.45	59	14399	65073	56212536
Acute kidney injury	31.93	30.45	11	14447	240752	56036857
Asthenia	31.74	30.45	25	14433	342948	55934661
Psychiatric symptom	31.35	30.45	18	14440	4826	56272783

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product dose omission issue	1366.83	28.23	830	18620	104756	31573138
Schizophrenia	1159.70	28.23	378	19072	10452	31667442
Inappropriate schedule of product administration	1049.31	28.23	544	18906	50279	31627615
Psychotic disorder	877.04	28.23	373	19077	21920	31655974
Hospitalisation	736.30	28.23	428	19022	49379	31628515
Blood prolactin increased	669.52	28.23	163	19287	1461	31676433
Treatment noncompliance	483.32	28.23	259	19191	25425	31652469
Off label use	481.80	28.23	801	18649	346473	31331421
Hallucination, auditory	469.57	28.23	192	19258	10168	31667726
Gynaecomastia	453.97	28.23	181	19269	8973	31668921
Incorrect dose administered	441.41	28.23	274	19176	35478	31642416
Injection site nodule	425.97	28.23	112	19338	1402	31676492
Akathisia	411.05	28.23	158	19292	7095	31670799
Extrapyramidal disorder	355.87	28.23	164	19286	11614	31666280
Therapeutic response decreased	324.03	28.23	202	19248	26307	31651587
Weight increased	310.04	28.23	314	19136	82633	31595261
Paranoia	306.49	28.23	143	19307	10412	31667482
Syringe issue	279.43	28.23	107	19343	4749	31673145
Psychotic symptom	279.00	28.23	81	19369	1491	31676403
Delusion	277.22	28.23	139	19311	11858	31666036
Sexual dysfunction	271.64	28.23	111	19339	5857	31672037
Refusal of treatment by patient	238.91	28.23	95	19355	4666	31673228
Dystonia	234.84	28.23	118	19332	10107	31667787
Blood prolactin abnormal	223.67	28.23	60	19390	814	31677080
Sedation	220.30	28.23	140	19310	18825	31659069
Therapeutic product effect decreased	218.95	28.23	170	19280	31452	31646442
Aggression	214.79	28.23	180	19270	37111	31640783
Drug ineffective	208.84	28.23	621	18829	394952	31282942
Underdose	206.13	28.23	116	19334	12491	31665403
Tardive dyskinesia	172.81	28.23	79	19371	5480	31672414
Anosognosia	170.60	28.23	48	19402	785	31677109
Schizoaffective disorder	162.89	28.23	51	19399	1224	31676670
Injection site pain	162.85	28.23	149	19301	34485	31643409
Disturbance in social behaviour	162.24	28.23	55	19395	1708	31676186
Dyskinesia	152.51	28.23	116	19334	20794	31657100
Galactorrhoea	151.96	28.23	38	19412	383	31677511
Suicidal ideation	145.19	28.23	143	19307	36263	31641631
Neuroleptic malignant syndrome	141.93	28.23	102	19348	16767	31661127
Erectile dysfunction	136.52	28.23	105	19345	19130	31658764
Device leakage	122.87	28.23	62	19388	5351	31672543
Abnormal behaviour	122.81	28.23	108	19342	23720	31654174
Product administered at inappropriate site	121.54	28.23	45	19405	1815	31676079
Diarrhoea	120.20	28.23	34	19416	352375	31325519
Product leakage	119.62	28.23	32	19418	429	31677465
Injection site mass	118.18	28.23	62	19388	5802	31672092
Condition aggravated	113.19	28.23	285	19165	163724	31514170
Breast enlargement	109.27	28.23	30	19420	446	31677448
Accidental exposure to product	107.11	28.23	74	19376	11421	31666473
Suicide attempt	105.44	28.23	122	19328	37126	31640768
Drooling	102.56	28.23	46	19404	3049	31674845
Product quality issue	101.50	28.23	82	19368	16029	31661865
Psychosexual disorder	101.00	28.23	21	19429	82	31677812
Product administration error	99.02	28.23	79	19371	15168	31662726
Hallucination	97.66	28.23	131	19319	46279	31631615
Adverse event	96.82	28.23	81	19369	16624	31661270
Acute kidney injury	95.24	28.23	27	19423	279687	31398207
Hyperprolactinaemia	93.50	28.23	35	19415	1456	31676438
Needle issue	92.93	28.23	51	19399	5222	31672672
Mania	90.05	28.23	61	19389	9116	31668778
Metabolic disorder	88.67	28.23	45	19405	3929	31673965
Anaemia	88.35	28.23	13	19437	213509	31464385
Parkinsonism	87.68	28.23	56	19394	7580	31670314
Product use issue	85.73	28.23	137	19313	56622	31621272
Imprisonment	85.68	28.23	25	19425	468	31677426
Pneumonia	78.78	28.23	55	19395	335257	31342637
Sepsis	76.84	28.23	4	19446	151925	31525969
Psychiatric symptom	75.36	28.23	38	19412	3273	31674621
Product use in unapproved indication	72.11	28.23	176	19274	98995	31578899
Injection site reaction	70.64	28.23	58	19392	11593	31666301
Personality change	69.99	28.23	41	19409	4754	31673140
Catatonia	67.22	28.23	40	19410	4774	31673120
Wrong technique in product usage process	66.90	28.23	92	19358	33251	31644643
Agitation	66.20	28.23	119	19331	54050	31623844
Dyspnoea	65.24	28.23	69	19381	343410	31334484
Abdominal pain	64.89	28.23	7	19443	145945	31531949
Eye movement disorder	61.65	28.23	35	19415	3826	31674068
Retrograde ejaculation	61.49	28.23	18	19432	341	31677553
Social avoidant behaviour	61.11	28.23	32	19418	2981	31674913
Nausea	60.56	28.23	60	19390	307887	31370007
Incorrect route of product administration	58.30	28.23	52	19398	11621	31666273
Toxicity to various agents	57.24	28.23	20	19430	181467	31496427
Breast tenderness	56.52	28.23	20	19430	707	31677187
Muscle rigidity	55.29	28.23	47	19403	9850	31668044
Flat affect	54.57	28.23	20	19430	783	31677111
Pyrexia	54.40	28.23	64	19386	303776	31374118
Anxiety	54.26	28.23	150	19300	90883	31587011
Priapism	53.33	28.23	34	19416	4586	31673308
Arthralgia	47.19	28.23	17	19433	151407	31526487
Wrong product administered	46.31	28.23	32	19418	4936	31672958
Haemoglobin decreased	46.21	28.23	7	19443	112668	31565226
Cough	45.79	28.23	13	19437	134801	31543093
Asthenia	43.87	28.23	44	19406	224711	31453183
Breast discharge	43.52	28.23	9	19441	34	31677860
Fatigue	42.48	28.23	89	19361	335117	31342777
Rash	42.19	28.23	37	19413	201449	31476445
Irritability	41.22	28.23	60	19390	22829	31655065
Product packaging issue	41.20	28.23	15	19435	576	31677318
Mental impairment	40.87	28.23	39	19411	9493	31668401
Thinking abnormal	40.78	28.23	31	19419	5542	31672352
Restlessness	40.29	28.23	60	19390	23301	31654593
Pruritus	39.08	28.23	14	19436	125153	31552741
Investigation	39.02	28.23	16	19434	850	31677044
Atrial fibrillation	38.58	28.23	11	19439	113772	31564122
Intentional self-injury	38.29	28.23	44	19406	13271	31664623
Renal failure	38.15	28.23	14	19436	123316	31554578
Hypotension	37.74	28.23	42	19408	204576	31473318
Cardiac failure congestive	37.41	28.23	3	19447	79384	31598510
Medication error	37.16	28.23	57	19393	22715	31655179
Decreased appetite	34.72	28.23	26	19424	153191	31524703
Device malfunction	34.32	28.23	35	19415	9231	31668663
Adverse drug reaction	34.18	28.23	58	19392	25143	31652751
Respiratory failure	34.04	28.23	10	19440	101439	31576455
Persecutory delusion	34.03	28.23	20	19430	2332	31675562
Ejaculation failure	33.90	28.23	14	19436	757	31677137
Blood creatinine increased	33.33	28.23	7	19443	89071	31588823
Infection	31.57	28.23	6	19444	81925	31595969
Pain	30.58	28.23	42	19408	186717	31491177
Vomiting	30.44	28.23	57	19393	223916	31453978
Drug interaction	30.20	28.23	51	19399	208492	31469402
Injection site rash	30.05	28.23	22	19428	3714	31674180
Extra dose administered	29.59	28.23	21	19429	3379	31674515
Psychiatric decompensation	29.11	28.23	17	19433	1959	31675935
Tremor	29.09	28.23	108	19342	76312	31601582
Libido decreased	28.82	28.23	23	19427	4413	31673481
Platelet count decreased	28.74	28.23	16	19434	110419	31567475
Depression	28.65	28.23	121	19329	90694	31587200
Back pain	28.26	28.23	16	19434	109397	31568497

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Schizophrenia	1430.32	25.28	419	21518	16349	70890158
Blood prolactin increased	1079.48	25.28	247	21690	3507	70903000
Inappropriate schedule of product administration	882.42	25.28	496	21441	107059	70799448
Product dose omission issue	833.67	25.28	621	21316	216847	70689660
Galactorrhoea	769.30	25.28	184	21753	3194	70903313
Psychotic disorder	707.47	25.28	306	21631	37395	70869112
Injection site nodule	596.93	25.28	150	21787	3220	70903287
Blood prolactin abnormal	573.48	25.28	140	21797	2656	70903851
Off label use	560.52	25.28	894	21043	742166	70164341
Disturbance in social behaviour	545.09	25.28	145	21792	3922	70902585
Hospitalisation	544.70	25.28	331	21606	82237	70824270
Sexual dysfunction	529.84	25.28	158	21779	6523	70899984
Anosognosia	523.86	25.28	131	21806	2754	70903753
Dystonia	505.13	25.28	200	21737	19506	70887001
Extrapyramidal disorder	491.68	25.28	199	21738	20551	70885956
Treatment noncompliance	487.77	25.28	253	21684	46321	70860186
Hallucination, auditory	473.21	25.28	187	21750	18141	70888366
Incorrect dose administered	456.71	25.28	274	21663	66445	70840062
Akathisia	405.56	25.28	150	21787	12143	70894364
Sedation	388.96	25.28	218	21719	46513	70859994
Amenorrhoea	381.66	25.28	124	21813	6806	70899701
Metabolic disorder	379.31	25.28	128	21809	7912	70898595
Dyskinesia	375.89	25.28	204	21733	40870	70865637
Personality change	355.48	25.28	125	21812	8745	70897762
Gynaecomastia	315.45	25.28	107	21830	6716	70899791
Suicide attempt	312.01	25.28	231	21706	79279	70827228
Syringe issue	304.24	25.28	98	21839	5230	70901277
Hyperprolactinaemia	292.73	25.28	91	21846	4322	70902185
Delusion	268.47	25.28	127	21810	19038	70887469
Paranoia	265.21	25.28	122	21815	17166	70889341
Psychotic symptom	252.56	25.28	71	21866	2367	70904140
Tardive dyskinesia	248.12	25.28	99	21838	9830	70896677
Weight increased	244.62	25.28	336	21601	241995	70664512
Refusal of treatment by patient	213.54	25.28	85	21852	8385	70898122
Aggression	213.27	25.28	151	21786	48295	70858212
Schizoaffective disorder	205.40	25.28	58	21879	1965	70904542
Neuroleptic malignant syndrome	191.26	25.28	112	21825	25895	70880612
Injection site mass	181.41	25.28	96	21841	18247	70888260
Product use in unapproved indication	166.02	25.28	258	21679	207220	70699287
Underdose	158.79	25.28	104	21833	29279	70877228
Injection site pain	156.05	25.28	187	21750	117432	70789075
Product administered at inappropriate site	140.68	25.28	49	21888	3327	70903180
Suicidal ideation	140.25	25.28	138	21799	69458	70837049
Abnormal behaviour	138.58	25.28	102	21835	34607	70871900
Diarrhoea	136.71	25.28	37	21900	783304	70123203
Therapeutic response decreased	135.04	25.28	125	21812	58328	70848179
Device leakage	134.36	25.28	63	21874	9245	70897262
Parkinsonism	123.31	25.28	70	21867	15255	70891252
Blood glucose increased	119.30	25.28	153	21784	102829	70803678
Product leakage	114.92	25.28	30	21907	751	70905756
Nausea	114.22	25.28	61	21876	852027	70054480
Drooling	111.27	25.28	47	21890	5389	70901118
Product use issue	110.69	25.28	199	21738	179738	70726769
Drug ineffective	107.05	25.28	571	21366	939181	69967326
Arthralgia	103.73	25.28	16	21921	503374	70403133
Insurance issue	96.67	25.28	38	21899	3623	70902884
Hallucination	94.16	25.28	117	21820	76143	70830364
Accidental exposure to product	93.40	25.28	74	21863	27977	70878530
Breast discharge	92.50	25.28	24	21913	586	70905921
Needle issue	90.90	25.28	51	21886	10864	70895643
Erectile dysfunction	90.80	25.28	55	21882	13507	70893000
Psychiatric symptom	89.86	25.28	43	21894	6601	70899906
Catatonia	87.35	25.28	45	21892	8088	70898419
Pain	79.82	25.28	48	21889	628768	70277739
Abdominal pain	74.85	25.28	9	21928	342118	70564389
Dyspnoea	74.82	25.28	77	21860	769983	70136524
Anaemia	70.27	25.28	19	21918	403404	70503103
Injection site abscess	68.08	25.28	23	21914	1423	70905084
Injection site reaction	65.59	25.28	79	21858	49773	70856734
Sudden death	64.66	25.28	53	21884	21011	70885496
Cough	63.29	25.28	12	21925	325365	70581142
Joint swelling	62.54	25.28	4	21933	253207	70653300
Tremor	62.15	25.28	144	21793	155480	70751027
Acute kidney injury	60.48	25.28	36	21901	474588	70431919
Fatigue	60.05	25.28	102	21835	824217	70082290
Mania	58.65	25.28	46	21891	17128	70889379
Product administration error	56.57	25.28	57	21880	29466	70877041
Mental impairment	56.32	25.28	45	21892	17210	70889297
Incorrect route of product administration	54.19	25.28	53	21884	26439	70880068
Social avoidant behaviour	53.60	25.28	27	21910	4629	70901878
Breast enlargement	53.50	25.28	19	21918	1365	70905142
Imprisonment	52.34	25.28	15	21922	536	70905971
Pruritus	51.88	25.28	21	21916	345539	70560968
Vomiting	51.32	25.28	65	21872	593046	70313461
Condition aggravated	51.13	25.28	264	21673	427371	70479136
Drug hypersensitivity	50.35	25.28	10	21927	262449	70644058
Eye movement disorder	49.35	25.28	30	21907	7410	70899097
Muscle rigidity	49.18	25.28	43	21894	18607	70887900
Psychiatric decompensation	48.68	25.28	22	21915	2965	70903542
Adverse drug reaction	47.73	25.28	70	21867	53274	70853233
Pulmonary embolism	47.32	25.28	130	21807	155737	70750770
Pyrexia	47.03	25.28	72	21865	606880	70299627
Abdominal discomfort	46.05	25.28	6	21931	214652	70691855
Rash	45.14	25.28	55	21882	510507	70396000
Injection site swelling	45.09	25.28	61	21876	43096	70863411
Pneumonia	44.98	25.28	72	21865	596160	70310347
Restlessness	44.71	25.28	60	21877	42068	70864439
Product quality issue	44.46	25.28	51	21886	30510	70875997
Mental disorder	44.28	25.28	49	21888	28191	70878316
Headache	43.86	25.28	70	21867	580335	70326172
Retrograde ejaculation	43.84	25.28	11	21926	234	70906273
Blood creatine phosphokinase increased	43.13	25.28	72	21865	61191	70845316
Abdominal pain upper	42.53	25.28	5	21932	193597	70712910
Breast tenderness	42.47	25.28	18	21919	2080	70904427
Agitation	42.41	25.28	91	21846	93284	70813223
Anxiety	42.36	25.28	157	21780	220173	70686334
Drug intolerance	40.45	25.28	10	21927	225677	70680830
Psychosexual disorder	40.24	25.28	9	21928	114	70906393
Sepsis	39.83	25.28	13	21924	244532	70661975
Rhabdomyolysis	39.73	25.28	90	21847	95670	70810837
Nasopharyngitis	39.53	25.28	10	21927	222196	70684311
Injection site induration	38.97	25.28	28	21909	9140	70897367
Asthenia	38.68	25.28	51	21886	457615	70448892
Toxicity to various agents	38.38	25.28	37	21900	382135	70524372
Back pain	38.26	25.28	18	21919	271134	70635373
Intentional self-injury	36.56	25.28	47	21890	31603	70874904
Infection	36.51	25.28	10	21927	210775	70695732
Wrong technique in product usage process	35.96	25.28	71	21866	68627	70837880
Depression	35.93	25.28	139	21798	198835	70707672
Irritability	35.41	25.28	51	21886	38174	70868333
Haemoglobin decreased	35.04	25.28	10	21927	205149	70701358
Device malfunction	35.02	25.28	36	21901	19048	70887459
Disease progression	34.52	25.28	4	21933	156668	70749839
Blunted affect	32.76	25.28	10	21927	446	70906061
Oculogyric crisis	32.10	25.28	16	21921	2682	70903825
Alopecia	31.54	25.28	11	21926	198479	70708028
Peripheral swelling	31.43	25.28	17	21920	236546	70669961
Adverse event	30.71	25.28	55	21882	49406	70857101
Injection site infection	30.54	25.28	14	21923	1950	70904557
Extra dose administered	30.42	25.28	22	21915	7255	70899252
Urinary tract infection	30.07	25.28	20	21917	248749	70657758
Bipolar disorder	29.54	25.28	22	21915	7586	70898921
Pain in extremity	29.32	25.28	35	21902	328047	70578460
Hypertension	29.31	25.28	29	21908	296004	70610503
Terminal dribbling	29.29	25.28	5	21932	12	70906495
Prolactin-producing pituitary tumour	29.16	25.28	7	21930	123	70906384
Investigation	28.60	25.28	14	21923	2257	70904250
Decreased appetite	27.78	25.28	32	21905	304748	70601759
Flat affect	27.70	25.28	13	21924	1910	70904597
Delirium	27.53	25.28	67	21870	74547	70831960
Swelling	27.39	25.28	12	21925	188527	70717980
Poor personal hygiene	27.25	25.28	9	21928	519	70905988
Saccadic eye movement	27.17	25.28	7	21930	166	70906341
Salivary hypersecretion	26.69	25.28	26	21911	12899	70893608
Menstruation irregular	26.64	25.28	17	21920	4571	70901936
Thinking abnormal	26.32	25.28	25	21912	12026	70894481
Cardiac failure congestive	26.30	25.28	5	21932	135452	70771055
Ejaculation failure	26.27	25.28	8	21929	354	70906153
Neuropathy peripheral	26.14	25.28	4	21933	126892	70779615
Soliloquy	26.14	25.28	9	21928	590	70905917
Tension	26.11	25.28	16	21921	4008	70902499
Contraindicated product administered	26.07	25.28	5	21932	134607	70771900
Renal failure	25.98	25.28	13	21924	189057	70717450
Pleural effusion	25.59	25.28	5	21932	132859	70773648

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
FDA EPC	N0000175430	Atypical Antipsychotic
MeSH PA	D014150	Antipsychotic Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018492	Dopamine Antagonists
MeSH PA	D065127	Dopamine D2 Receptor Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D058830	Serotonin 5-HT2 Receptor Antagonists
MeSH PA	D018490	Serotonin Agents
MeSH PA	D012702	Serotonin Antagonists
MeSH PA	D014149	Tranquilizing Agents
CHEBI has role	CHEBI:35471	psychotropic drugs
CHEBI has role	CHEBI:37890	alpha-adrenergic receptor blockaders
CHEBI has role	CHEBI:37955	H1 receptor antagonists
CHEBI has role	CHEBI:48279	serotonin antagonists
CHEBI has role	CHEBI:48561	dopaminergic antagonists
CHEBI has role	CHEBI:49103	drug metabolites
CHEBI has role	CHEBI:63726	neuroprotective agents
CHEBI has role	CHEBI:65191	atypical antipsychotic agent

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Schizophrenia	indication	58214004	DOID:5419
Priapism	contraindication	6273006	DOID:9286
Suicidal thoughts	contraindication	6471006
Weight gain finding	contraindication	8943002
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Senile dementia	contraindication	15662003
Agranulocytosis	contraindication	17182001	DOID:12987
Lowered convulsive threshold	contraindication	19260006
Myocardial infarction	contraindication	22298006	DOID:5844
Stenosis of intestine	contraindication	23065003
Short bowel syndrome	contraindication	26629001	DOID:10605
Hypovolemia	contraindication	28560003
Orthostatic hypotension	contraindication	28651003
Torsades de pointes	contraindication	31722008
Parkinsonism	contraindication	32798002
Crohn's disease	contraindication	34000006
Dehydration	contraindication	34095006
Hypokalemia	contraindication	43339004
Conduction disorder of the heart	contraindication	44808001
Low blood pressure	contraindication	45007003
Chronic heart failure	contraindication	48447003
Hyperlipidemia	contraindication	55822004	DOID:1168
Cerebrovascular disease	contraindication	62914000	DOID:6713
Substance abuse	contraindication	66214007
Diabetes mellitus	contraindication	73211009	DOID:9351
Extrapyramidal disease	contraindication	76349003
Diffuse Lewy body disease	contraindication	80098002
Hyperglycemia	contraindication	80394007	DOID:4195
Leukopenia	contraindication	84828003	DOID:615
Tardive dyskinesia	contraindication	102449007
Increased intestinal motility	contraindication	102624003
Prolonged QT interval	contraindication	111975006
Seizure disorder	contraindication	128613002
Hypomagnesemia	contraindication	190855004
Angina pectoris	contraindication	194828000
Impaired renal function disorder	contraindication	197663003
Metabolic syndrome X	contraindication	237602007	DOID:14221
Hyperprolactinemia	contraindication	237662005	DOID:12700
Esophageal dysmotility	contraindication	266434009	DOID:9192
Neutropenic disorder	contraindication	303011007	DOID:1227
At risk for aspiration	contraindication	371736008
Impaired cognition	contraindication	386806002
Breastfeeding (mother)	contraindication	413712001
Obesity	contraindication	414916001	DOID:9970
Gastrointestinal hypomotility	contraindication	421807004
Acquired torsion dystonia	contraindication	433493000
Congenital long QT syndrome	contraindication	442917000
Carcinoma of female breast	contraindication	447782002
Esophageal Compression	contraindication
Intestinal Cystic Fibrosis	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.78	Basic
pKa2	1.52	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
117MG/0.75ML (117MG/0.75ML)	INVEGA SUSTENNA	JANSSEN PHARMS	N022264	July 31, 2009	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	9439906	Jan. 26, 2031	DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)
117MG/0.75ML (117MG/0.75ML)	INVEGA SUSTENNA	JANSSEN PHARMS	N022264	July 31, 2009	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	9439906	Jan. 26, 2031	DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)
117MG/0.75ML (117MG/0.75ML)	INVEGA SUSTENNA	JANSSEN PHARMS	N022264	July 31, 2009	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	9439906	Jan. 26, 2031	TREATMENT OF SCHIZOAFFECTIVE DISORDER AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
117MG/0.75ML (117MG/0.75ML)	INVEGA SUSTENNA	JANSSEN PHARMS	N022264	July 31, 2009	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	9439906	Jan. 26, 2031	TREATMENT OF SCHIZOPHRENIA
156MG/ML (156MG/ML)	INVEGA SUSTENNA	JANSSEN PHARMS	N022264	July 31, 2009	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	9439906	Jan. 26, 2031	DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)
156MG/ML (156MG/ML)	INVEGA SUSTENNA	JANSSEN PHARMS	N022264	July 31, 2009	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	9439906	Jan. 26, 2031	DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)
156MG/ML (156MG/ML)	INVEGA SUSTENNA	JANSSEN PHARMS	N022264	July 31, 2009	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	9439906	Jan. 26, 2031	TREATMENT OF SCHIZOAFFECTIVE DISORDER AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
156MG/ML (156MG/ML)	INVEGA SUSTENNA	JANSSEN PHARMS	N022264	July 31, 2009	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	9439906	Jan. 26, 2031	TREATMENT OF SCHIZOPHRENIA
234MG/1.5ML (156MG/ML)	INVEGA SUSTENNA	JANSSEN PHARMS	N022264	July 31, 2009	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	9439906	Jan. 26, 2031	DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)
234MG/1.5ML (156MG/ML)	INVEGA SUSTENNA	JANSSEN PHARMS	N022264	July 31, 2009	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	9439906	Jan. 26, 2031	DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)
234MG/1.5ML (156MG/ML)	INVEGA SUSTENNA	JANSSEN PHARMS	N022264	July 31, 2009	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	9439906	Jan. 26, 2031	TREATMENT OF SCHIZOAFFECTIVE DISORDER AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
234MG/1.5ML (156MG/ML)	INVEGA SUSTENNA	JANSSEN PHARMS	N022264	July 31, 2009	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	9439906	Jan. 26, 2031	TREATMENT OF SCHIZOPHRENIA
39MG/0.25ML (39MG/0.25ML)	INVEGA SUSTENNA	JANSSEN PHARMS	N022264	July 31, 2009	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	9439906	Jan. 26, 2031	DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)
39MG/0.25ML (39MG/0.25ML)	INVEGA SUSTENNA	JANSSEN PHARMS	N022264	July 31, 2009	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	9439906	Jan. 26, 2031	DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)
39MG/0.25ML (39MG/0.25ML)	INVEGA SUSTENNA	JANSSEN PHARMS	N022264	July 31, 2009	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	9439906	Jan. 26, 2031	TREATMENT OF SCHIZOAFFECTIVE DISORDER AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
39MG/0.25ML (39MG/0.25ML)	INVEGA SUSTENNA	JANSSEN PHARMS	N022264	July 31, 2009	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	9439906	Jan. 26, 2031	TREATMENT OF SCHIZOPHRENIA
78MG/0.5ML (78MG/0.5ML)	INVEGA SUSTENNA	JANSSEN PHARMS	N022264	July 31, 2009	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	9439906	Jan. 26, 2031	DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)
78MG/0.5ML (78MG/0.5ML)	INVEGA SUSTENNA	JANSSEN PHARMS	N022264	July 31, 2009	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	9439906	Jan. 26, 2031	DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)
78MG/0.5ML (78MG/0.5ML)	INVEGA SUSTENNA	JANSSEN PHARMS	N022264	July 31, 2009	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	9439906	Jan. 26, 2031	TREATMENT OF SCHIZOAFFECTIVE DISORDER AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
78MG/0.5ML (78MG/0.5ML)	INVEGA SUSTENNA	JANSSEN PHARMS	N022264	July 31, 2009	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	9439906	Jan. 26, 2031	TREATMENT OF SCHIZOPHRENIA
273MG/0.875ML (273MG/0.875ML)	INVEGA TRINZA	JANSSEN PHARMS	N207946	May 18, 2015	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	10143693	April 5, 2036	REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE 4-9 MONTHS AGO
273MG/0.875ML (273MG/0.875ML)	INVEGA TRINZA	JANSSEN PHARMS	N207946	May 18, 2015	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	10143693	April 5, 2036	REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE MORE THAN 9 MONTHS AGO
410MG/1.315ML (311.79MG/ML)	INVEGA TRINZA	JANSSEN PHARMS	N207946	May 18, 2015	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	10143693	April 5, 2036	REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE 4-9 MONTHS AGO
410MG/1.315ML (311.79MG/ML)	INVEGA TRINZA	JANSSEN PHARMS	N207946	May 18, 2015	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	10143693	April 5, 2036	REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE MORE THAN 9 MONTHS AGO
546MG/1.75ML (312MG/ML)	INVEGA TRINZA	JANSSEN PHARMS	N207946	May 18, 2015	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	10143693	April 5, 2036	REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE 4-9 MONTHS AGO
546MG/1.75ML (312MG/ML)	INVEGA TRINZA	JANSSEN PHARMS	N207946	May 18, 2015	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	10143693	April 5, 2036	REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE MORE THAN 9 MONTHS AGO
819MG/2.625ML (312MG/ML)	INVEGA TRINZA	JANSSEN PHARMS	N207946	May 18, 2015	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	10143693	April 5, 2036	REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE 4-9 MONTHS AGO
819MG/2.625ML (312MG/ML)	INVEGA TRINZA	JANSSEN PHARMS	N207946	May 18, 2015	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	10143693	April 5, 2036	REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE MORE THAN 9 MONTHS AGO
1.092GM/3.5ML (312MG/ML)	INVEGA HAFYERA	JANSSEN PHARMS	N207946	Aug. 30, 2021	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	11304951	May 7, 2041	REINITIATION OF SCHIZOPHRENIA TREATMENT WHEREIN MORE THAN 6 MONTHS 3 WEEKS BUT LESS THAN 8 MONTHS HAVE ELAPSED SINCE THE LAST DOSE
1.092GM/3.5ML (312MG/ML)	INVEGA HAFYERA	JANSSEN PHARMS	N207946	Aug. 30, 2021	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	11324751	May 7, 2041	TREATMENT OF SCHIZOPHRENIA BY ADMINISTERING A DOSE UP TO TWO WEEKS BEFORE OR THREE WEEKS AFTER THE SCHEDULED SIX-MONTH DOSE
1.560GM/5ML (312MG/ML)	INVEGA HAFYERA	JANSSEN PHARMS	N207946	Aug. 30, 2021	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	11304951	May 7, 2041	REINITIATION OF SCHIZOPHRENIA TREATMENT WHEREIN MORE THAN 6 MONTHS 3 WEEKS BUT LESS THAN 8 MONTHS HAVE ELAPSED SINCE THE LAST DOSE
1.560GM/5ML (312MG/ML)	INVEGA HAFYERA	JANSSEN PHARMS	N207946	Aug. 30, 2021	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	11324751	May 7, 2041	TREATMENT OF SCHIZOPHRENIA BY ADMINISTERING A DOSE UP TO TWO WEEKS BEFORE OR THREE WEEKS AFTER THE SCHEDULED SIX-MONTH DOSE

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
1.092GM/3.5ML (312MG/ML)	INVEGA HAFYERA	JANSSEN PHARMS	N207946	Aug. 30, 2021	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	Aug. 30, 2024	NEW STRENGTH
1.560GM/5ML (312MG/ML)	INVEGA HAFYERA	JANSSEN PHARMS	N207946	Aug. 30, 2021	RX	SUSPENSION, EXTENDED RELEASE	INTRAMUSCULAR	Aug. 30, 2024	NEW STRENGTH

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	ANTAGONIST			DRUG LABEL	DRUG LABEL
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN	ANTAGONIST			DRUG LABEL	DRUG LABEL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	5.89	CHEMBL

External reference:

ID	Source
D05340	KEGG_DRUG
4029217	VUID
N0000181687	NUI
4025875	VANDF
4029217	VANDF
CHEBI:83807	CHEBI
CHEBI:82978	CHEBI
CHEMBL2107360	ChEMBL_ID
R8P8USM8FR	UNII
DB01267	DRUGBANK_ID
679314	RXNORM
166838	MMSL
23004	MMSL
26654	MMSL
d06297	MMSL
011888	NDDF
013207	NDDF
117004004	SNOMEDCT_US
425483000	SNOMEDCT_US
426276000	SNOMEDCT_US
706896003	SNOMEDCT_US
C2719626	UMLSCUI
D000068882	MESH_DESCRIPTOR_UI
C0753678	UMLSCUI
9852746	PUBCHEM_CID
7977	INN_ID
115237	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
INVEGA SUSTENNA	HUMAN PRESCRIPTION DRUG LABEL	1	50458-560	INJECTION	39 mg	INTRAMUSCULAR	NDA	35 sections
INVEGA SUSTENNA	HUMAN PRESCRIPTION DRUG LABEL	1	50458-560	INJECTION	39 mg	INTRAMUSCULAR	NDA	35 sections
INVEGA SUSTENNA	HUMAN PRESCRIPTION DRUG LABEL	1	50458-561	INJECTION	78 mg	INTRAMUSCULAR	NDA	35 sections
INVEGA SUSTENNA	HUMAN PRESCRIPTION DRUG LABEL	1	50458-561	INJECTION	78 mg	INTRAMUSCULAR	NDA	35 sections
INVEGA SUSTENNA	HUMAN PRESCRIPTION DRUG LABEL	1	50458-562	INJECTION	117 mg	INTRAMUSCULAR	NDA	35 sections
INVEGA SUSTENNA	HUMAN PRESCRIPTION DRUG LABEL	1	50458-562	INJECTION	117 mg	INTRAMUSCULAR	NDA	35 sections
INVEGA SUSTENNA	HUMAN PRESCRIPTION DRUG LABEL	1	50458-563	INJECTION	156 mg	INTRAMUSCULAR	NDA	35 sections
INVEGA SUSTENNA	HUMAN PRESCRIPTION DRUG LABEL	1	50458-563	INJECTION	156 mg	INTRAMUSCULAR	NDA	35 sections
INVEGA SUSTENNA	HUMAN PRESCRIPTION DRUG LABEL	1	50458-564	INJECTION	234 mg	INTRAMUSCULAR	NDA	35 sections
INVEGA SUSTENNA	HUMAN PRESCRIPTION DRUG LABEL	1	50458-564	INJECTION	234 mg	INTRAMUSCULAR	NDA	35 sections
INVEGA TRINZA	HUMAN PRESCRIPTION DRUG LABEL	1	50458-606	INJECTION, SUSPENSION, EXTENDED RELEASE	273 mg	INTRAMUSCULAR	NDA	40 sections
INVEGA TRINZA	HUMAN PRESCRIPTION DRUG LABEL	1	50458-606	INJECTION, SUSPENSION, EXTENDED RELEASE	273 mg	INTRAMUSCULAR	NDA	40 sections
INVEGA TRINZA	HUMAN PRESCRIPTION DRUG LABEL	1	50458-607	INJECTION, SUSPENSION, EXTENDED RELEASE	410 mg	INTRAMUSCULAR	NDA	40 sections
INVEGA TRINZA	HUMAN PRESCRIPTION DRUG LABEL	1	50458-607	INJECTION, SUSPENSION, EXTENDED RELEASE	410 mg	INTRAMUSCULAR	NDA	40 sections
INVEGA TRINZA	HUMAN PRESCRIPTION DRUG LABEL	1	50458-608	INJECTION, SUSPENSION, EXTENDED RELEASE	546 mg	INTRAMUSCULAR	NDA	40 sections
INVEGA TRINZA	HUMAN PRESCRIPTION DRUG LABEL	1	50458-608	INJECTION, SUSPENSION, EXTENDED RELEASE	546 mg	INTRAMUSCULAR	NDA	40 sections
INVEGA TRINZA	HUMAN PRESCRIPTION DRUG LABEL	1	50458-609	INJECTION, SUSPENSION, EXTENDED RELEASE	819 mg	INTRAMUSCULAR	NDA	40 sections
INVEGA TRINZA	HUMAN PRESCRIPTION DRUG LABEL	1	50458-609	INJECTION, SUSPENSION, EXTENDED RELEASE	819 mg	INTRAMUSCULAR	NDA	40 sections
INVEGA HAFYERA	HUMAN PRESCRIPTION DRUG LABEL	1	50458-611	INJECTION, SUSPENSION, EXTENDED RELEASE	1092 mg	INTRAMUSCULAR	NDA	38 sections
INVEGA HAFYERA	HUMAN PRESCRIPTION DRUG LABEL	1	50458-612	INJECTION, SUSPENSION, EXTENDED RELEASE	1560 mg	INTRAMUSCULAR	NDA	38 sections